Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Sperling AS, Guerra VA, Kennedy JA, Yan Y, et al. Blood 2022;140:1753-1763.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sperling AS, Guerra VA, Kennedy JA, Yan Y, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood 2022;140:1753-1763.
PMID: 35512188